Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1997-04-11
1999-03-23
Chambers, Jasemine C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
4353201, 435325, 4352523, 43525411, 435254, 536 231, 536 232, 536 235, 536 243, 536 2431, C12Q 168, C07H 2100, C12N 1512, C12N 1563
Patent
active
058857770
DESCRIPTION:
BRIEF SUMMARY
RELATED APPLICATION
This application is a national stage application of PCT/EP95/03990 filed Oct. 10, 1995 under 35 USC 371.
BACKGROUND OF THE INVENTION
The present invention concerns a new phosphatidyl-inositol-3-kinase (PI3K.gamma.), a nucleic acid which codes for it, an antibody directed against the protein as well as the diagnostic and therapeutic use of the protein, of the nucleic acid and of the antibody.
Phosphatidylinositol-kinases belong, together with specific phospholipases, to an enzyme group which catalyses the formation of intracellular messenger substances from the membrane lipid phosphatidyl inositol (PI). The activity of these enzymes is regulated by extracellular effectors such as hormones, growth factors and neurotransmitters. It is assumed that the PI dependent messenger substances are involved among other processes in the regulation of important cells functions such as cell proliferation, secretion of cellular constituents, endocytotic processes, the targetted movement of certain cells, controlled changes of the cytoskeleton. Correspondingly the physiological importance of the PI kinases and phospholipases correlates with a series of disease states involving changes of the functions of these enzymes.
From various experimental results it is possible to conclude that the product of the reaction catalysed by PI3 kinase, PI-3,4,5 triphosphate plays an important role in the regulation of the following physiological cell functions:
Mitogens such as growth factors and cytokines generally lead to a stimulation of the PI 3 kinase activity in cells capable of division. The oncogenic transformation of cells is also often accompanied by an increase in the measurable PI 3 kinase activity (Varticovski et al., Biochim. Biophys. Acta 1226, 1-11 (1994), Berggren et al., Cancer Research 53, 4297-4302 (1993), Soldi et al., Oncogene 9, 2253-2260 (1994)). Inhibitors of PI 3 kinase are able to inhibit the PDGF-stimulated growth of normal connective tissue cells or smooth muscle cells and the proliferation of src-supratransformed fibroblasts (cancer cells) (Berggren et al., Cancer Research 53, 4297-4302 (1993), Vlahos et al., J.Biol.Chem. 269, 5241-5248 (1994)). Berggren et al., have speculated that the tumoristatic effect of ether lipid analogues is mainly based on their inhibitory action on PI 3 kinase.
The differentiation of the nerve cell line PC12 is suppressed by wortmannin an inhibitor of PI 3 kinase (Kimurea et al., J.Biol.Chem. 269, 18961-18967 (1994)). These findings as well as a clinical study in which there was shown to be a selective loss of PI 3 kinase activity in the brain of Alzheimer patients (Bothmer et al., Dementia 5, 6-11 (1994)) indicate that the enzyme has an important function in the formation and maintenance of nerve tissue.
Microscopically visible changes of cells often progress with the involvement of the cytoskeleton. A series of results shows that at least some of these processes are regulated by PI 3 kinase and its enzymatic products (PI3,4,5,P.sub.3, PI3,4P.sub.2 and PI3P). Thus the membrane ruffling of epidermal cells induced by insulin or PDGF can be suppressed by the PI 3 kinase inhibitor wortmannin (Kotani et al., EMBO J. 13, 2313-2321 (1994), Wennstrom et al., Curr. Biol. 4, 385-393 (1994)).
Basophilic leucocytes are able to secrete histamine--a mediator of inflammations and allergic symptoms. The cytoskeleton of the cells is involved in this secretion process. Yano et al., J. Biol.Chem. 268, 25846-25856 (1993) were able to show that the antibody-induced histamine secretion can in turn be inhibited by the PI 3 kinase inhibitor wortmannin i.e. it is apparently controlled by 3-phosphorylated phosphoinositides.
Investigations on yeast mutants show that one form of PI 3 kinase (Vps 34) is involved in these organisms in the selective distribution of proteins towards the yeast vacuoles (Schu et al., Science 260, 88-91 (1993)). Similar mechanisms may be the basis of the insulin-stimulated translocation of glucose transport protein (GLUT 4) from the interior of the cell to the
REFERENCES:
James, "Toward gene-inhibition therapy: a review of progress and prospects n the field of antiviral antisense nucleic acids and ribozymes", Antiviral Chemistry & Chemotherapy 2(4): 191-214, 1991.
Orkin et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy", issued by the U.S. National Insitutes of Health, Dec. 1995.
Gura, "Antisense has growing pains", Science 270:575-577, Oct. 1995.
Science, Aug. 4, 1995, 269 (5224) P690-3, Stoyanov et al., Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase.
Molecular and Cellular Biology, vol. 13, No. 12, Dec. 1993 pp. 7677-7688, Hu et al, Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and . . .
Hanck Theodor
Stoyanov Borislav
Wetzker Reinhard
Chambers Jasemine C.
Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.v.
Priebe Scott D.
LandOfFree
Cloning, expression and characterization of a novel form of phos does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloning, expression and characterization of a novel form of phos, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning, expression and characterization of a novel form of phos will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2123949